Abu-Rumeileh S.,Abdelhak A.,Foschi M.,Tumani H.,Otto M. .2021 .Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. , 268(4) : 1133-1170.
Brown T.E.,Feasby T.E. .1984 .Conduction block and denervation in Guillain-Barré polyneuropathy. Brain, 107 : 219-39.
Dantal J. .2013 .Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol., 38(4) : 275-84.
Darweesh S.K.,Polinder S.,M.J. Mulder S,Baena C.P.,Leeuwen O.H.,Franco B.C.,Jacobs P.A. van Doorn .2014 .Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst., 19(1) : 24-35.
Davidson A.I.,Halstead S.K.,Goodfellow J.A.,Chavada G.,Mallik A.,Overell J.,Lunn M.P.,McConnachie A.,Willison P. van Doorn and H. J. .2017 .Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study. J Peripher Nerv Syst., 22(1) : 4-12.
DeStefano H.M.,Bodenstab P.A.,Offit P.A. .2019 .Principal Controversies in Vaccine Safety in the United States. Clin Infect Dis, 69(4) : 726-731.
Dimachkie M.,Barohn M. .2013 .Guillain-Barré syndrome and variants. Neurol Clin., 31(2) : 491-510.
Eldar A.H.,Chapman J A.H. .2014 .Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmun Rev., 13(4-5) : 525-30.
Ellul M.A.,Benjamin L.,Singh B.,Lant S.,Michael B.D.,Easton A.,Kneen R.,Defres S.,Sejvar J.,Solomon T. .2020 .Neurological associations of COVID-19. , 19(9) : 767-783.
Finsterer J.,Scorza F.A.,Scorza C.A.,Fiorini A. C. .2021 .Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit. , 79(10) : 924-928.
Garg M. .2017 .Respiratory Involvement in Guillain-Barre Syndrome: The Uncharted Road to Recovery. J Neurosci Rural Pract, 8(3) : 325-326.
Gatherer D.,Kohl A .2016 .Zika virus: a previously slow pandemic spreads rapidly through the Americas. , 97(2) : 269-273.
Guillan G.,Barré J. A.,Strohl A .1916 .Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquid cephalorachidien sans réaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Méd, 40 : 1462-70.
Hagen S.S.,Ousman S.S. .2020 .The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System. Front Aging Neurosci. , 613628 : 613628.
Hegen H.,Ladstätter F.,Auer M.,Berek K.,Di Pauli F.,Walde J.,Wanschitz J.,Zinganell A.,Deisenhammer F. .2021 .Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. Eur J Neurol., 28(3) : 965-973.
Harms M. .2011 .Inpatient management of guillain-barré syndrome. Neurohospitalist, 10(2) : PMC3726082-84.
Hughes R.A.,Wijdicks E.F.,Barohn R.,Benson E.,Cornblath D.R.,Hahn A.F.,Meythaler J.M.,Miller R.G.,Sladky J.T.,J.C. J.T. .2003 .Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. , 61(6) : 736-40.
Hughes R.A.,Swan A.V.,Raphaël J.C.,Annane D.,R. van Koningsveld and van Doorn PA D. .2007 .Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain, 130 : 2245-57.
Hughes R.A.,Brassington R.,Gunn A.A.,P.A. van Doorn A.A. .2016 .Corticosteroids for Guillain-Barré syndrome. PMID: 27775812; PMCID: PMC6464149., 10(10) : .
Islam Z.,Papri N.,Ishaque T.,Alam A.U.,Islam I. Jahan B.,Mohammad Q.D. .2019 .Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. Ann Clin Transl Neurol, 6(2) : 324-332.
Khan F.,Amatya B. .2012 .Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med, 48(3) : 507-22.
Korinthenberg R.,Eckenweiler M.,Fuchs M. .2021 .Severe Locked-In-Like Guillain-Barré's Syndrome: Dilemmas in Diagnosis and Treatment. , 52(1) : 19-26.
Kuwabara S. and N.,Yuki S. and N. .2013 .Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol, 12(12) : 1180-8.
Liu J.,Wang L.N.,McNicol E.D. .2015 .4):CD009950. PMID: 25855461; PMCID: PMC6361619., 10 : .
Liu S.,Dong C.,Ubogu E.E. .2018 .Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother., 14(11) : 2568-2579.
Liu H.,Lv H.G.,Zhang R. .2023 .Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report. World J Clin Cases, 11(26) : 6274-6279.
Liu S.,Zhang W.W.,Zhang H.L. .2024 .Guillain-Barré syndrome: immunopathogenesis and therapeutic targets. Expert Opin Ther Targets, 18 : 1-13.
Matarneh A.S.,Al-Battah A.H.,Farooqui K.,Ghamoodi M.,Alhatou M. .2021 .COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep., 9, 10(9) : 4756.
Merchant H. .2022 .Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions. Postgrad Med, 10(1161) : 98.
Nelson K.E. .2012 .Invited commentary: Influenza vaccine and Guillain-Barre syndrome--is there a risk? Am J Epidemiol. , 175(11) : 1129-32.
Packiyarajah P.,Sundaresan and M.S.M. Nusair K.T. .2023 .. Rare Sensory Ataxic Variant of Guillain-Barre Syndrome: A Case Report., Cureus, 10(6) : .
Patone M.,Handunnetthi L.,Saatci D.,Pan J.,Katikireddi S.V.,Razvi S.,Hunt D.,Mei X.W.,Dixon S.,Zaccardi F.,Khunti K.,Watkinson P.,Coupland A.A.C.,Doidge J.,Harrison D.A.,Ravanan R.,Sheikh A.,Robertson C.,Hippisley-Cox J. .2021 .Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med, 27(12) : 2144-2153.
Pimentel V.,Luchsinger V.W.,Carvalho G.L.,Alcará A.M.,Esper N.B.,Marinowic D.,Zanirati G.,Costa J.C. .2022 .Guillain-Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun Health, 100578 : 100578.
Rinaldi S. .2013 .Update on Guillain-Barré syndrome. J Peripher Nerv Syst., 18(2) : 99-112.
Ropper A.H. .1992 .The Guillain-Barré syndrome. N Engl J Med, 326(17) : 1130-6.
Ryan M.M. .2013 .Pediatric Guillain-Barré syndrome. Curr Opin Pediatr., 25(6) : 689-93.
Saeed M.L.,Baloch B Kaleem,Mahmud S.N.,Khan M.T.,Qureshi M.S.S.,Shad Z.S.,Hussain S.W.,Munawar K.,Qadeer A.,Abdullah A,Yuki N. .2013 .Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry, 22984203(5) : 576-83.
Shahrizaila N.,Lehmann H.C.,Kuwabara S. .2021 .Guillain-Barré syndrome. Lancet, 397(10280) : 1214-1228.
Spasovski G.,Vanholder R.,Allolio B.,Annane D.,Ball D. Bichet S.,D S.,Fenske W.,Hoorn E.J.,Ichai C.,Joannidis M.,Soupart A.,Zietse R.,Haller M.,E. Nagler; M. .2014 .Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol., 170(3) : G1-47.
Toscano G.,Palmerini F.,Ravaglia S.,Ruiz L.,Invernizzi P.,Cuzzoni M.G.,Franciotta D.,Baldanti F.,Daturi R.,Postorino P.,Cavallini A.,Micieli G.,Engl J Med N .2020 .Guillain-Barré Syndrome Associated with SARS-CoV-2. , 382(26) : 2574-2576.
Uncini A,Kuwabara S. .2012 .Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol., 123(8) : 1487-95.
van den Berg ,C. Walgaard J.,Drenthen C.,Fokke J.B.,Jacobs P.A. van Doorn .2014 .Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol, 10(8) : 469-82.
Vellozzi C.,Iqbal S.,Broder K. .2014 .Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis, 58(8) : 1149-55.
Perera V.N.,I. Nachamkin V.N.,Ung H.,Patterson J.H.,M.J. McConville P.J.,Coloe B.N.,Fry B.N. .2007 .Molecular mimicry in Campylobacter jejuni: role of the lipo-oligosaccharide core oligosaccharide in inducing antiganglioside antibodies. FEMS Immunology & Medical Microbiology, 50(1) : 27-36.
Wakerley B.R.,Uncini A.,N. A. .2014 .GuillainBarré and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol, 10(9) : 537-44.
Walgaard C.,Jacobs B.C.,P.A. van Doorn B.C. .2011 .Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs, 16(1) : 105-20.
Wang Y.Z.,Lv H.,Shi Q.G.,Fan X.T.,Li L.,Yi Wong A.H.,Hao Y.L.,Si C.P.,Li C.L.,Yuki N. .2015 .Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome. Sci Rep., 10 : 13931.
Willison C.S.,Goodyear C.S. .2013 .Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol, 34(9) : 453-9.
Ye Y.,Zhu D.,Wang K.,J. Wu J.,Feng D.,Ma Y.,Xing X.,Jiang X. .2010 .Clinical and electrophysiological features of the 2007 Guillain-Barré syndrome epidemic in northeast China. Muscle Nerve, 42(3) : 311-4.
Yikilmaz A,Doganay S.,Gumus H.,Per H.,Kumandas S.,Coskun A .2010 .Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst., 26(8) : 1103-8.
Yoshikawa K.,Kuwahara M.,Morikawa M.,Kusunoki S. .2020 .Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. , 10(6) : .
Yuki N. and H.P.,Hartung N. and H.P. .2012 .Guillain-Barré syndrome. N Engl J Med, 366(24) : 2294-304.
Zhang L.,Ma L.,Zhou L.,Sun Q,Fang Q .2023 .Miller-Fisher syndrome with positive anti-GD1b and anti-GM1 antibodies combined with multiple autoimmune antibodies: A case report. Medicine (Baltimore), 10(34) : .